A Phase 4 interventional study of sIPV and MMR in Poliomyelitis, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Months to 22 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Sinovac Biotech Co., Ltd · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis — 3 open to participants now, 3 under way, none of them phase 3. Poliovirus Vaccine, Inactivated · Poliomyelitis.
Among the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, this one is the 8th largest by enrollment, is one of 2 that started in 2024, is one of 11 in phase 4, and was the 14th registered.
275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.
Browse Poliomyelitis studies →3 of the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis are open now, in 1 country. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 3 mo–50 yrs · Healthy volunteers
Institute of Medical Biology, Chinese Academy of Medical Sciences · Sites in China
Ages 2 mo–2 mo · Healthy volunteers
International Centre for Diarrhoeal Disease Research, Bangladesh
Ages 42 days–48 days · Healthy volunteers
By country, each count listing its studies:
Poliovirus Vaccine, Inactivated: first FDA approval 2002 (Pediarix). What it is approved for, and how studies give it, is on its page →
Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Months to 22 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 4 · Phase 4 11
First in 2009; this study’s year is marked. 2 started in 2024.
This study's enrollment of 889 is above the median of 478 across 250 interventional studies indexed under Poliomyelitis.
Median enrollment 672 across the 18 interventional studies. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
Sinovac Biotech Co., Ltd is the lead sponsor of 93 studies on the registry; 18 are open to participants now.
15 studies in Poliomyelitis by Sinovac Biotech Co., Ltd: 2 open now, 3 under way, none of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 15 studies in Poliomyelitis by Sinovac Biotech Co., Ltd, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 4, and was the 13th registered.
Sinovac Biotech Co., Ltd’s Poliomyelitis studies by the year they started, since 2016.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sinovac Biotech Co., Ltd’s 15 in Poliomyelitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an Open-labeled, Randomized, Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of Booster Dose of Sabin Strain Inactivated Poliovirus Vaccine (Vero cell) (sIPV) Co-administered with Measles, Mumps, Rubella (MMR) Combined Live Attenuated Vaccine and Inactivated Hepatitis A (Hep-A) Vaccine.
The trial plans to enroll 960 infants aged 18 months (+4 months) who had completed three primary doses of sIPV vaccine and were assigned in a 2:2:2:1:1 ratio to four groups including trial group 1, trial group 2, control group 1, control group 2, control group 2, with informed consent from the participant's guardian. Trial group 1 receive one dose of sIPV co-administered with one dose of MMR vaccine. Trial group 2 receive one dose of sIPV co-administered with one dose of inactivated hepatitis A vaccine. Control group 1 receive one dose of sIPV, control group 2 receive one dose of MMR vaccine, and control group 3 receive one dose of inactivated hepatitis A vaccine. About 3.0 ml of venous blood will be collected from all participants before and 30 days after vaccination for antibody detection. Immediate reactions will be observed for 30 minutes after vaccination, and adverse events occured from 0 to day 30 after vaccination will be collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vaccination with sIPV+MMR
Biological: sIPV · Biological: MMR
vaccination with sIPV+HepA-I
Biological: sIPV · Biological: HepA-I
vaccination with sIPV
Biological: sIPV
vaccination with MMR
Biological: MMR
vaccination with HepA-I
Biological: HepA-I
seroconversion rates (SCRs) of sIPV neutralizing antibody against different poliovirus serotypes (Type I, II and III)
-The SCRs of neutralizing antibody against different poliovirus serotypes (Type I, II and III) at day 30 after sIPV vaccination.
Time frame: 30 days
SCRs of anti-meascles IgG antibodies
SCRs of anti-measles IgG antibodies 30 days after vaccination
Time frame: 30 days
SCRs of anti-mumps IgG antibodies
SCRs of anti-mumps IgG antibodies 30 days after vaccination
Time frame: 30 days
SCRs of anti-rubella IgG antibodies
SCRs of anti-rubella IgG antibodies 30 days after vaccination
Time frame: 30 days
SCRs of anti-hepatitis A IgG antibodies
SCRs of anti-hepatitis A antibodies 30 days after vaccination
Time frame: 30 days
Seropositivity rates (SPRs) and GMC of anti-measles virus IgG antibodies
SPRs and GMC of anti-measles virus IgG antibodies 30 days after vaccination.
Time frame: 30 days
SPRs and GMC of anti-mumps virus IgG antibodies
SPRs and GMC of anti-mumps virus IgG antibodies 30 days after vaccination;
Time frame: 30 days
SPRs and GMC of anti-rubella virus IgG antibodies
SPRs and GMC of anti-rubella virus IgG antibodies 30 days after vaccination;
Time frame: 30 days
SPRs and GMC of anti- hepatitis A virus IgG antibodies
SPRs and GMC of anti- hepatitis A virus IgG antibodies 30 days after vaccination;
Time frame: 30 days
Geometric Mean Titer (GMT) of sIPV neutralizing antibody against different poliovirus serotypes (Type I, II and III)
-GMTs of antibody of neutralizing antibody against different poliovirus serotypes (Type I, II and III) at day 30 after sIPV vaccination;
Time frame: 30 days
- SPRs of neutralizing antibodies against different poliovirus serotypes (Type I, II and III)
\- SPRs of neutralizing antibodies against different poliovirus serotypes (Type I, II and III) at day 30 after vaccination.
Time frame: 30 days
- Incidence of adverse reactions (ARs)
\- Incidence of ARs from 0 to 30 days after vaccination;
Time frame: 30 days
- Incidence of serious adverse events (SAEs)
\- Incidence of SAEs 0\~30 days after vaccination.
Time frame: 30 days
Plan to share: No
Ran from Aug 2024 to primary completion in Sep 2025, 13 months.
Of 30 phase 4 interventional studies under Poliomyelitis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 25. This study's 13 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Poliovirus Vaccine, Inactivated · Measles-Mumps-Rubella Vaccine